

# CRISPR THERAPEUTICS PUBLIC OFFERING: THE ADVISORS

*Posted on 7 July 2020*



**Category:** [Capital Markets](#)

**Tags:** [Alex Nikitine](#), [André Kuh](#), [Christian Lütolf](#), [CRISPR Therapeutics](#), [Ex-Featured](#), [Frank Gerhard](#), [Homburger](#), [Janine Corti](#), [Jasmin Eicher](#), [Lorenzo Togni](#), [Maurus Winzap](#), [Rafael Zemp](#), [Walder Wyss](#)



**CRISPR Therapeutics**, a Swiss gene editing company focused on developing transformative gene-based medicines, [carried out](#) an underwritten offering of 6,982,143 shares (including overallotment shares), resulting in gross proceeds of approximately USD 520 million. Goldman Sachs & Co. LLC, BofA Securities and Jefferies were acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners were acting as co-managers for the offering. CRISPR is headquartered in Zug, Switzerland. CRISPR's common shares are listed on Nasdaq.

## The advisors

**Walder Wyss [acted as Swiss counsel to CRISPR](#) in connection with the transaction.**

**The team was led by partner Alex Nikitine (Corporate/M&A, Capital Markets - pictured right) and managing associate Christian Lütolf (Corporate/M&A, Capital Markets) and further included managing associates Rafael Zemp (Corporate/M&A, Capital Markets), André Kuhn (Notary), trainee Jasmin Eicher (Capital Markets), partner Maurus Winzap (Tax) and counsel Janine Corti (Tax).**

**Homburger [acted as legal counsel](#) to Goldman Sachs & Co. LLC, BofA Securities, Inc.**

**and Jefferies LLC as the joint book-running managers and representatives of the several underwriters in the offering. The team comprised partner Frank Gerhard (pictured left) and associate Lorenzo Togni (both Corporate/ M&A and Capital Markets).**